|First use||1983 (Finland)|
|Trade names||Norplant, Jadelle, Sino-implant (II), others|
|Failure rates (first year)|
|Duration effect||up to 5 years|
|Reversibility||Provided correctly inserted|
|User reminders||Alternative method required after 5 years|
|Advantages and disadvantages|
|Weight||No proven effect|
|Period disadvantages||irregular light spotting|
|Benefits||No further user action needed|
|Possible scarring and difficulty in removal|
Levonorgestrel-releasing implant, sold under the brand name Jadelle and Implanon among others, are devices that release levonorgestrel for birth control. It is one of the most effective forms of birth control with a one-year failure rate around 0.05%. The device is placed under the skin and lasts for up to five years. It may be used by women who have a history of pelvic inflammatory disease and therefore cannot use an intrauterine device. Following removal fertility quickly returns.
It is generally well tolerated with few significant side effects. Side effects may include irregular menstrual periods, no periods, headaches, and breast pain. Use is not recommended in people with significant liver disease. The levonorgestrel implant is a type of long-acting reversible birth control. It primarily works by stopping ovulation and by thickening the mucus around the cervix.
A levonorgestrel-releasing implant was approved for medical use in 1983 in Finland and in the United States in 1990. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about US$8.93–13.29 per set. Levonorgestrel implants are approved in more than 60 countries and used by more than seven million women. As of 2015 it is approved but not available in the United States.
Levonorgestrel-releasing implant is 99% – 99.95% effective at preventing pregnancy, and is one of the most reliable, though not the most available, forms of birth control. Levonorgestrel-releasing implant prevents pregnancy through multiple methods: by preventing ovulation, which means that no eggs are released for fertilization; by thickening the mucus of the cervix, which prevents sperm from entering; and by thinning the lining of the uterus, which makes implantation of an embryo less likely.
The way in which levonorgestrel-releasing implant causes these effects is by use of hormones. A small amount of the hormone progestin is released through the capsules continuously, more during the first year and a half, but then at a level similar to most contraceptive pills afterward. Like all hormonal contraception, levonorgestrel-releasing implant does not protect against sexually transmitted infections.
Implantable contraceptives are especially effective in the developing world, as they do not require daily administration or access to a hospital to be effective. In addition, no continual contraceptive supplies (pills, condoms, etc.) are necessary, and it is a highly effective, low cost contraceptive over the long term.
Levonorgestrel-releasing implant should not be used in women with liver disease, breast cancer, or blood clots. Women who believe they may already be pregnant or those with vaginal bleeding should first see a physician. However, since it does not contain estrogen like some birth control pills, older women, women who smoke, and women with high blood pressure are not restricted from using the system.
This section does not cite any sources. (March 2014) (Learn how and when to remove this template message)
After three months of using, women will need to schedule a follow-up appointment to monitor blood pressure and discuss any concerns. Side effects may include irregular menstrual periods for the first approximately three months, including periods lasting longer than normal, bleeding or spotting between periods, heavy bleeding, or going with no period for the mentioned period of time.  Sometimes, pain, itching or infection at the site of the implant will occur. Ovarian cysts may also occur, but usually do not require treatment, although they can cause pain even if benign.
Levonorgestrel-releasing implant is implanted under the skin in the upper arm of a woman, by creating a small incision and inserting the capsules in a fanlike shape. Insertion usually takes 15 minutes and the capsules can sometimes be seen under the skin, although usually they look like small veins. They can also be felt under the skin. Once inserted, the contraceptive works within 24 hours and lasts up to five years.
Levonorgestrel-releasing implant can be removed by creating a second incision and withdrawing the capsules. It is normally removed when the five-year period is over, or if:
- Pregnancy is desired
- Different birth control is preferred
- Complications arise
Normally removal is not complicated; removal difficulties have been reported with a frequency of 6.2%, based on 849 removals. Removal difficulties include: multiple incisions, capsule fragments remaining, pain, multiple visits, deep placement, lengthy removal procedure, or other.
If desired, a new implant can be inserted at the time of removal.
It was developed by Sheldon J. Segal and Horacio Croxatto at the Population Council beginning in 1966, with the first clinical trial in Chile in 1974. It was first approved in Finland on November 23, 1983, where it was manufactured by Leiras Oy Pharmaceuticals. The original Norplant consisted of a set of six small (2.4 mm × 34 mm) silicone capsules, each filled with 36 mg of levonorgestrel implanted under the skin in the upper arm and effective for five years. The original (six capsule) Norplant's production has been phased out; USAID's contract ran until December 2006. The original (six capsule) Norplant was approved by the U.S. Food and Drug Administration (FDA) on December 10, 1990, and marketed in the United States in 1991 by Wyeth Pharmaceuticals. Norplant distribution in the United States ended in 2002; limited supplies still remained in the U.S. until 2004. Norplant was withdrawn from the UK market in 1999. Production of Norplant was discontinued globally in 2008.
Norplant II (Norplant-2, Jadelle), also developed by the Population Council and manufactured by Schering Oy, consists of two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix, instead of six capsules. It was approved May 31, 1996 by the FDA as being effective for three years; it was subsequently approved November 22, 2002 by the FDA as being effective for five years. Jadelle has not been marketed in the United States; Jadelle is the successor to the original Norplant in USAID's contract beginning January 2007.
Society and culture
By 1996, more than 50,000 women had filed lawsuits, including 70 class actions, against Wyeth and/or its subsidiaries, or doctors who prescribed Norplant. Wyeth never lost a Norplant lawsuit, even in cases which came before a jury.
On August 26, 1999, after winning 3 jury verdicts, 20 pretrial summary judgments and the dismissal of 14,000 claims, Wyeth offered out-of-court cash settlements of $1,500 each to about 36,000 women who contended that they had not been adequately warned about possible side effects of Norplant such as irregular menstrual bleeding, headaches, nausea and depression. Wyeth said that most of the plaintiffs experienced routine side effects described in Norplant's labeling information. Wyeth did not admit to any wrongdoing, saying the settlement offer "was purely a business decision," noting "our legal success has come at a steep price because lawsuits are time-consuming, expensive, and have a chilling effect on research," and that it would continue to offer Norplant and would contest "any and all new lawsuits aggressively."
About 32,000 women accepted the out-of-court $1,500 settlements. On August 14, 2002, Wyeth won partial summary judgment and dismissal of the claims of the 2,960 remaining plaintiffs who had not accepted Wyeth's out-of-court settlement offer.
In August 2000, Wyeth suspended shipments of Norplant in the United States because during regular quality assurance monitoring, representative samples of seven lots distributed beginning October 20, 1999 tested within product specifications, but at the lower end of the release rate specification for shelf life stability, raising concerns about those lots' contraceptive effectiveness. Wyeth recommended that women who had Norplant capsules from those lots implanted use backup contraception until they determined the clinical relevance of the atypically low levels of levonorgestrel release.
On July 26, 2002, Wyeth announced that data from investigations conducted in women with Norplant capsules from the suspect lots did not suggest less contraceptive effectiveness than that reported in clinical trials, and that therefore backup contraception could be safely discontinued. Wyeth also announced that due to limitations in product component supplies, they did not plan to resume marketing the six-capsule Norplant system in the United States.
Jadelle was added to the Pharmaceutical Management Agency's (Pharmac) schedule and subsequently subsidized in August 2010. Medical professionals raised concerns during a consultation process indicating preference for a product which is easier to insert. The agreement between Bayer New Zealand and Pharmac was conditional on Bayer New Zealand providing adequate training to ensure doctors are comfortable in the insertion and removal technique.
Some American legislators have unsuccessfully attempted to provide financial incentives to women on welfare who agree to use Norplant. For example, in Kansas, Republican Kerry Patrick introduced legislation that would grant welfare recipients a one-time payment of $500 to use Norplant, followed by a $50 bonus each year the implants remained in place." Some judges have offered Norplant implants as a voluntary alternative to jail time for certain women convicted of child abuse or drug abuse during pregnancy. Two days after the 1990 FDA approval of Norplant, an editorial in The Philadelphia Inquirer suggested reducing the size of the black underclass by offering welfare mothers increased benefits if they agreed to use Norplant. Eleven days later the Inquirer apologized for their "misguided and wrongheaded" editorial and for their suggestion of offering incentives for Norplant use. Critics such as the ACLU argued that such uses are coercive and discriminatory, and compared such uses to early 20th-century American eugenics. In Killing the Black Body, black feminist Dorothy Roberts links such uses of Norplant to a "white mainstream" that is allegedly determined to "demonize, even criminalize" poor black women's lives and reproductive choices.
Within two years of Norplant's FDA approval, legislators in thirteen U.S. states had proposed nearly two dozen bills offering incentives for, or requiring use of Norplant by welfare mothers; none of these proposals passed.
The first big city to aggressively promote the use of Norplant was Baltimore. Baltimore targeted teenagers because the birthrate was three times higher than other states. In Baltimore, about ten percent of girls between ages 15 and 17 gave birth during 1990. Young mothers would often drop out of school and struggle to raise the child in poverty. The mayor at the time, Kurt Schmoke, pushed for laws that would give teen girls more access to Norplant. Norplant was eventually given to teen girls at schools without parental consent. Programs were designed for, and performed in, predominantly black schools. Laurence G. Paquin Middle School became the first school to provide Norplant to their students. Paquin Middle School had 355 female students but only 5 of them were not black. Their program started off as a pilot program and soon other urban high schools like San Fernando High School in Los Angeles and Crane High School in Chicago's West Side adopted the program of providing Norplant to their students. Because of a focus on predominantly black schools, questions of racism arose amongst black community leaders.
- Nexplanon, another subdermal contraceptive implant
- Shoupe, Donna; Jr, Daniel R. Mishell (2015). The Handbook of Contraception: A Guide for Practical Management (2 ed.). Humana Press. p. 141. ISBN 9783319201856. Archived from the original on 2017-09-23. Cite uses deprecated parameter
- "Effectiveness of Family Planning Methods" (PDF). CDC. Archived (PDF) from the original on 29 December 2016. Retrieved 1 January 2017. Cite uses deprecated parameter
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 373. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. Cite uses deprecated parameter
- Corson, S. L.; Derman, R. J. (1995). Fertility Control. CRC Press. p. 195. ISBN 9780969797807. Archived from the original on 2017-09-23. Cite uses deprecated parameter
- Medicine, Institute of; Policy, Division of Health Sciences; Development, Committee on Contraceptive Research and (1998). Contraceptive Research, Introduction, and Use: Lessons From Norplant. National Academies Press. p. 107. ISBN 9780309059855. Archived from the original on 2017-09-23. Cite uses deprecated parameter
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. Cite uses deprecated parameter
- "Levonorgestrel". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016. Cite uses deprecated parameter
- Kulczycki, Andrzej (2013). Critical Issues in Reproductive Health. Springer Science & Business Media. p. 16. ISBN 9789400767225. Archived from the original on 2017-09-23. Cite uses deprecated parameter
- Siving, Irving; Nash, Harold (2002). Jadelle Levonorgestrel Rod Implants: A Summary of Scientific Data and Lessons Learned from Programmatic Experience. Population Council. p. 4. ISBN 9780878341054. Archived from the original on 2017-09-23. Cite uses deprecated parameter
- . (2006). "Norplant side effects". RxList.com. New York: WebMD. Archived from the original on February 9, 2002. Retrieved August 16, 2006. Cite uses deprecated parameter
- Subcommittee for Workshop on Implant Contraceptives, Committee on Contraceptive Research and Development, Division of Health Policy, Institute of Medicine (March 9, 1998). "Appendix B: Norplant: historical background". In Harrison, Polly F.; Rosenfield, Allan (eds.). Contraceptive research, introduction, and use: lessons from Norplant. Washington, D.C.: National Academy Press. pp. 107–114. ISBN 978-0-309-05985-5.CS1 maint: multiple names: authors list (link)
- Sivin, Irving; Nash, Harold; Waldman, Sandra (February 28, 2002). "Development and introduction of contraceptive implants". Jadelle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. New York, N.Y.: Population Council. pp. 1–6. ISBN 0-87834-105-6.
- Gunardi, Eka Rusdianto; Affandi, Biran; Muchtar, Armen (January 2011). "Monoplant® the Indonesian implant: the overview of implant and its development". Indoesian Journal of Obstetrics and Gynecology. 35 (1): 40–46. ISSN 0303-7924. Archived from the original on 2014-07-25. Cite uses deprecated parameter
- Roy, Subir (1985). "Current status of Norplant subdermal implants for contraception". In Runnebaum, Benno; Rabe, Thomas; Kiesel, Ludwig (eds.). Future aspects in contraception: proceedings of an international symposium held in Heidelberg, 5–8 September 1984; Part 2, Female contraception. Boston, Mass.: MTP Press. pp. 95–106. ISBN 0-85200-906-2.
The Finnish National Board of Health approved the NORPLANT sub-dermal implant system as a contraceptive method in Finland on 23 November 1983.
- Chin, Mona (1997). "Norplant: levonorgestrel implants". Berkeley: UC Berkeley Computer Science Undergraduate Association (Mona Chin's personal web page). Archived from the original on August 29, 2006. Retrieved August 17, 2006. Cite uses deprecated parameter
- Shelton, James D. (Office of Population, USAID) (March 24, 2006). "Future for implants". Baltimore: The Johns Hopkins University, Bloomberg School of Public Health, Center for Communication Programs. Archived from the original on September 28, 2007. Retrieved August 17, 2006.CS1 maint: multiple names: authors list (link)
- Grimes, William (October 20, 2009). "Sheldon J. Segal, who developed contraceptives, dies at 83". The New York Times. Archived from the original on April 1, 2014. Retrieved October 22, 2009. Cite uses deprecated parameter
- BBC News (April 30, 1999). "Contraceptive implant withdrawn". London: BBC News. Retrieved August 16, 2006.
- Ahmed, Kabir; Deperthes, Bidia; Frederick, Beth; Ehlers, Suzanne; Kapp, Natalie; Paladines, Cindy; Siemerink, Marie Christine; Skibiak, John; Skorochod, Beth; Steiner, Markus; Townsend, John; Westley, Elizabeth (March 2012). "Contraceptive Commodities for Women's Health: Key Data and Findings" (PDF). New York: UNFPA (United Nations Population Fund). p. 4. Archived from the original (PDF) on June 11, 2014. Retrieved December 16, 2013.
Norplant (six rods each containing 36 mg of levonorgestrel, effective for five to seven years) was discontinued in 2008.Cite uses deprecated parameter
Caucus on New and Underused Reproductive Health Technologies (July 2013). "Contraceptive implants" (PDF). Brussels: Reproductive Health Supplies Coalition. Archived from the original (PDF) on December 17, 2013. Retrieved December 16, 2013.
Production of Norplant was discontinued in 2008 because the new generation of products—the two-rod implants, Jadelle and Sino-implant (II), and 1-rod implants, Implanon and Nexplanon/Implanon NXT—are easier to insert and remove.Cite uses deprecated parameter
Rademacher, Kate H.; Vahdat, Heather L.; Dorflinger, Laneta; Owen, Derek H.; Steiner, Markus J. (2014). "Global Introduction of a Low-Cost Contraceptive Implant". In Kulczycki, Adnrzej (ed.). Critical Issues in Reproductive Health. Dordrecht: Springer. p. . ISBN 978-94-007-6721-8.
Studies and field experience demonstrated that compared to Norplant, one- and two-rod implants are easier and quicker to remove. This advantage led to the replacement of Norplant by Jadelle and Implanon in health programs around the world; in 2008, global production of Norplant was discontinued (Ramchandran and Upadhyay 2007).
- Population Council (December 19, 2003). "Jadelle implants - general information". New York: Population Council. Archived from the original on January 4, 2004. Retrieved August 16, 2005.
- Shelton, James D. (Office of Population, USAID) (September 6, 2006). "New USAID award for contraceptive implants (Jadelle)". INFO (Information and Knowledge for Optimal Health) Project. Baltimore: The Johns Hopkins University, Bloomberg School of Public Health, Center for Communication Programs. Archived from the original on July 5, 2008. Retrieved January 6, 2007.CS1 maint: multiple names: authors list (link)
- Johnson, Erica; Smyth, Carmel; Jones, Colman (April 1, 2003). "Medical device lawsuits". Marketplace. Toronto: CBC News. Archived from the original on April 18, 2003. Retrieved July 28, 2006.
- ARHP (2006). "New developments in contraception: the single-rod implant" (PDF). Washington, D.C.: Association of Reproductive Health Professionals. Archived from the original (PDF) on April 22, 2006. Retrieved January 6, 2007.
- . (September 5, 1998). "Contraceptive maker wins woman's suit over side effects". The New York Times. p. A7. Archived from the original on November 7, 2012. Retrieved January 15, 2007. Cite uses deprecated parameter
- Morrow, David J. (August 27, 1999). "Maker of Norplant offers a settlement in suit over effects". The New York Times. p. A1. Archived from the original on March 7, 2016. Retrieved January 15, 2007. Cite uses deprecated parameter
- Manson, Pamela (August 27, 2002). "Federal judge dismisses Norplant damage claims". Texas Lawyer. New York: Law.com. Archived from the original on October 1, 2002. Retrieved January 15, 2007.
- FDA (September 13, 2000). "MedWatch - New safety information summaries 2000 - Norplant". Silver Spring, Md.: U.S. Food and Drug Administration. Archived from the original on November 19, 2000. Retrieved January 6, 2007.
- FDA (July 26, 2002). "Update on advisory for Norplant contraceptive kits". Silver Spring, Md.: U.S. Food and Drug Administration. Archived from the original on October 2, 2002. Retrieved January 6, 2007.
- Pharmaceutical Management Agency (July 1, 2010). "Notification: Jadelle (levonorgestrel 2 x 75 mg rods) funding proposal approved" (PDF). Wellington, New Zealand: Pharmaceutical Management Agency. Archived (PDF) from the original on July 24, 2011. Retrieved July 26, 2010. Cite uses deprecated parameter
- Roberts, Dorothy (1997). "Chapter 3. From Norplant to the Contraceptive Vaccine. The New Frontier of Population Control". Killing the Black Body: Race, Reproduction, and the Meaning of Liberty. New York: Pantheon. ISBN 0-679-44226-X.
- editorial (December 12, 1990). "Poverty and Norplant; can contraception reduce the underclass?". The Philadelphia Inquirer. p. A18. Archived from the original on November 27, 2015. Retrieved December 16, 2013. Cite uses deprecated parameter
- editorial (December 23, 1990). "An apology: the editorial on 'Norplant and poverty' was misguided and wrongheaded". The Philadelphia Inquirer. p. C04. Archived from the original on August 6, 2015. Retrieved December 16, 2013. Cite uses deprecated parameter
- ACLU (January 31, 1994). "Norplant: A New Contraceptive with the Potential for Abuse". New York: American Civil Liberties Union. Archived from the original on December 2, 2013. Retrieved November 24, 2013. Cite uses deprecated parameter
- Harrison, Polly F.; Rosenfield, Allan, eds. (1998). "Workshop Report". Contraceptive Research, Introduction, and Use: Lessons from Norplant. Washington, D.C.: National Academy Press. pp. ISBN 978-0-309-05985-5.
Davidson, Andrew R.; Kalmuss, Debra (April 1997). "Topics for our times: Norplant coercion—an overstated threat". American Journal of Public Health. 87 (4): 550–551. doi:10.2105/ajph.87.4.550. PMC 1380830. PMID 9146429. Retrieved December 16, 2013. , .
- Banisky, Sandy (December 3, 1992). "City officials planning to promote Norplant; teen-agers will be targeted for the 5-year contraceptive". The Baltimore Sun. p. 1A. Archived from the original on December 12, 2013. Retrieved December 9, 2013. Cite uses deprecated parameter